Quick Answer
REGENEREX PHARMA, INC. reported Operating Income of -$1.83 million for fiscal year 2025.
REGENEREX PHARMA, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$1.83M | +47.3% |
| 2024 | -$3.47M | -3503.8% |
| 2023 | -$96.2K | +23.8% |
| 2022 | -$126.3K | -190.9% |
| 2021 | -$43.4K | +43.6% |
| 2020 | -$77.0K | +16.1% |
| 2019 | -$91.7K | -85.5% |
| 2018 | -$49.5K | -1821.9% |
| 2017 | -$2.6K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$786.7K | -204.5% | -24.1% |
| June 30, 2025 | -$633.8K | -149.2% | -103.5% |
| December 31, 2024 | -$311.5K | -30.1% | -20.6% |
| September 30, 2024 | -$258.4K | +90.7% | -1.6% |
| June 30, 2024 | -$254.3K | -58.8% | -6.2% |
| December 31, 2023 | -$239.4K | -722.6% | +91.4% |
| September 30, 2023 | -$2.79M | -12855.4% | -1639.3% |
| June 30, 2023 | -$160.2K | -826.7% | -450.4% |
- REGENEREX PHARMA, INC. showed an increase of +47.3% in Operating Income compared to the prior fiscal year.
- Over the 2017–2025 period, REGENEREX PHARMA, INC.’s operating income has declined by 70871.5% (from -$2.6 thousand to -$1.83 million).
- The most recent figure is from REGENEREX PHARMA, INC.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 30, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: